Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01OLO
|
|||
| Former ID |
DNC000256
|
|||
| Drug Name |
AS602868
|
|||
| Synonyms |
Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin; Isopsoralen
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Discontinued in Phase 1 | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H14N4O3S
|
|||
| Canonical SMILES |
CC1=CC(=O)N(C1=O)NC2=NC(=NC3=C2C(=CC=C3)OC)C4=CC=CS4
|
|||
| InChI |
1S/C18H14N4O3S/c1-10-9-14(23)22(18(10)24)21-17-15-11(5-3-6-12(15)25-2)19-16(20-17)13-7-4-8-26-13/h3-9H,1-2H3,(H,19,20,21)
|
|||
| InChIKey |
GZGLPBNOIFLLRE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 219773-55-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11252, 474744, 906407, 5431451, 8157698, 14717697, 15171425, 24890472, 29229128, 48201986, 49759962, 49971731, 50764077, 53787425, 57326370, 57389038, 76715686, 81093330, 85174297, 90453137, 92234807, 103238743, 104323903, 117587177, 123110660, 124524901, 125352095, 126562821, 126677677, 129674058, 131317290, 132564007, 134339728, 134340138, 134977795, 137008662, 142432010, 162187543, 162220209, 162547815, 163410157, 163614306, 163643920, 165299549, 172089135, 172880200, 179316412, 184546839, 186014621, 198954101
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941) | |||
| REF 2 | Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. | |||
| REF 3 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.